Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.39 |
| ▸ | KDM6B | O15054 | 2/20 | 0.39 |
| ▸ | KDM5C | P41229 | 2/20 | 0.39 |
| ▸ | PHF8 | Q9UPP1 | 2/20 | 0.39 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA3 | P07451 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA6 | P23280 | 1/20 | 0.39 |
| ▸ | CA5A | P35218 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL644570 | 0.94 | EGLN1 (0.43) | EGLN1KDM6BKDM5CPHF8KDM2A | |
| Butane SCHEMBL2861696 | 0.90 | LMNA (0.41) | EGLN1KDM6BKDM5CPHF8KDM2A | |
| SCHEMBL4737199 | 0.87 | EGLN1 (0.45) | EGLN1KDM6BKDM5CPHF8KDM2A | |
| SCHEMBL645070 | 0.85 | CA12 (0.45) | CA12CA1CA2CA3CA4 | |
| SCHEMBL6178633 | 0.85 | CA12 (0.37) | EGLN1KDM6BKDM5CPHF8KDM2A | |
| SCHEMBL793167 | 0.82 | TSHR (0.52) | EPHX2LMNAKMT2ACYP1A2 | |
| SCHEMBL791222 | 0.82 | LMNA (0.50) | EPHX2LMNAMAPTKMT2A | |
| SCHEMBL8092417 | 0.81 | LMNA (0.53) | EPHX2LMNAMAPTKMT2A | |
| SCHEMBL4896865 | 0.81 | LMNA (0.53) | EPHX2LMNAMAPTKMT2A | |
| SCHEMBL8087700 | 0.81 | LMNA (0.53) | EPHX2LMNAMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1244648-B1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | GENZYME CORP (US) | 2009-04-15 | — | — | EP | disclosed |
| US-20070060591-A1 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION | 2007-03-15 | — | — | US | disclosed |
| US-7022717-B2 | Chemokine receptor binding heterocyclic compounds | ANORMED, INC. (CA) | 2006-04-04 | — | — | US | disclosed |
| US-20060069129-A1 | Chemokine receptor binding heterocyclic compounds | BRIDGER GARY J | 2006-03-30 | — | — | US | disclosed |
| US-20040102428-A1 | Chemokine receptor binding heterocyclic compounds | ANORMED CORPORATION (CA) | 2004-05-27 | — | — | US | disclosed |
| US-6667320-B2 | For therapy of infalmmation; asthma, cancer, arthritis, multiple sclerosis; prophylaxis of infection of target cells by a human immunodeficiency virus (HIV) | ANORMED (CA) | 2003-12-23 | — | — | US | disclosed |
| EP-1244648-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2002-10-02 | — | — | EP | disclosed |
| US-20020077339-A1 | Chemokine receptor binding heterocyclic compounds | ANORMED CORPORATION (CA) | 2002-06-20 | — | — | US | disclosed |
| WO-2001044229-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2001-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060591-A1 | Chemokine receptor binding heterocyclic compounds | CCR5, ACKR3, CCR2 | EGLN1 1442/4885KDM6B 3163/4885KDM5C 1342/4885 |
| US-20040102428-A1 | Chemokine receptor binding heterocyclic compounds | CCR5, ACKR3, CCR2 | EGLN1 1442/4885KDM6B 3163/4885KDM5C 1342/4885 |
| US-20020077339-A1 | Chemokine receptor binding heterocyclic compounds | CCR5, ACKR3, CCR2 | EGLN1 1442/4885KDM6B 3163/4885KDM5C 1342/4885 |
| US-20060069129-A1 | Chemokine receptor binding heterocyclic compounds | CCR5, ACKR3, CCR2 | EGLN1 1442/4885KDM6B 3163/4885KDM5C 1342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.